While the combination of immune checkpoint inhibitors with BRAF and MEK inhibitors has emerged as a promising therapeutic strategy for patients with BRAF-mutant melanoma, alternative approaches to overcoming resistance are currently under investigation. The gene discussed is BRAF; the disease is melanoma.